{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:44:43Z","timestamp":1793414683236,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["No. 964874 (REALMENT)"],"award-info":[{"award-number":["No. 964874 (REALMENT)"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["grant no. MC_ U120097115"],"award-info":[{"award-number":["grant no. MC_ U120097115"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Dopamine D2\/D3 receptor modulation with antipsychotics is thought to affect cognitive function, but causal evidence in humans is scant, and largely limited to single administrations. Clarifying this is of importance given the widespread use of antipsychotics, and to understand the role of D2\/D3 signalling in human cognition. We therefore conducted a double-blind, placebo-controlled crossover study following sustained administration of either a dopamine D2\/D3 receptor antagonist (amisulpride at 400\u2009mg daily) or a D2\/D3 partial agonist (aripiprazole at 10\u2009mg daily) to two separate samples of healthy humans (total n\u2009=\u200950) for 7 days per condition. We assessed cognitive function using a computerised visuospatial working memory (VS-WM) task, and sustained attention and response inhibition using the Sustained Attention to Response Task (SART). We found that both amisulpride and aripiprazole caused impairments in VS-WM function compared to placebo on the Balanced Integration Score (amisulpride: p\u2009=\u20090.0079; aripiprazole: p\u2009=\u20090.015). Both antipsychotics impaired VS-WM performance in terms of response latency (amisulpride: p\u2009=\u20095.5\u2009\u00d7\u200910<jats:sup>\u22127<\/jats:sup>; aripiprazole: p\u2009=\u20090.022), but did not affect response accuracy. Response latency deficits were not correlated with motor impairments induced by either drug, and we also found no effect of either drug on the SART measures, or on subjective alertness, suggesting that D2\/D3 antagonism or partial agonism did not cause a generalised cognitive or motor deficit but specifically impaired cognition during VS-WM. This study provides the first causal evidence in healthy humans that working memory function is impaired following either sustained antagonism or partial agonism of D2\/D3 receptors by antipsychotic drugs.<\/jats:p>","DOI":"10.1038\/s41380-025-03116-8","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T13:19:54Z","timestamp":1752931194000},"page":"5315-5325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2\/D3 antagonism, D2\/D3 partial agonism and placebo"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-8464","authenticated-orcid":false,"given":"Martin","family":"Osugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7849-4907","authenticated-orcid":false,"given":"Uzma","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9069-0700","authenticated-orcid":false,"given":"Pierluigi","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Chilimidos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1026-4626","authenticated-orcid":false,"given":"Valeria","family":"Finelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7874-0314","authenticated-orcid":false,"given":"George E.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Whitehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis Chika","family":"Onwordi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-0519","authenticated-orcid":false,"given":"Robin M.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-7661","authenticated-orcid":false,"given":"Tiago Reis","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1152-5323","authenticated-orcid":false,"given":"Mitul A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-1972","authenticated-orcid":false,"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"3116_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tics.2018.12.006","volume":"23","author":"T Ott","year":"2019","unstructured":"Ott T, Nieder A. Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci. 2019;23:213\u201334.","journal-title":"Trends Cogn Sci"},{"key":"3116_CR2","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.neuropsychologia.2009.09.023","volume":"48","author":"C Beste","year":"2010","unstructured":"Beste C, Willemssen R, Saft C, Falkenstein M. Response inhibition subprocesses and dopaminergic pathways: Basal ganglia disease effects. Neuropsychologia. 2010;48:366\u201373.","journal-title":"Neuropsychologia"},{"key":"3116_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.112679","volume":"205","author":"TJ Brozoski","year":"1979","unstructured":"Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205:929\u201332.","journal-title":"Science"},{"key":"3116_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1523\/JNEUROSCI.4653-03.2004","volume":"24","author":"AG Phillips","year":"2004","unstructured":"Phillips AG, Ahn S, Floresco SB. Magnitude of dopamine release in medial prefrontal cortex predicts accuracy of memory on a delayed response task. J Neurosci. 2004;24:547\u201353.","journal-title":"J Neurosci"},{"key":"3116_CR5","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1152\/jn.1997.78.5.2795","volume":"78","author":"M Watanabe","year":"1997","unstructured":"Watanabe M, Kodama T, Hikosaka K. Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol. 1997;78:2795\u20138.","journal-title":"J Neurophysiol"},{"key":"3116_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuropharm.2019.01.003","volume":"148","author":"CA Marshall","year":"2019","unstructured":"Marshall CA, Brodnik ZD, Mortensen OV, Reith MEA, Shumsky JS, Waterhouse BD, et al. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention. Neuropharmacology. 2019;148:178\u201388.","journal-title":"Neuropharmacology"},{"key":"3116_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00760-3","volume":"14","author":"B Wulaer","year":"2021","unstructured":"Wulaer B, Kunisawa K, Tanabe M, Yanagawa A, Saito K, Mouri A, et al. Pharmacological blockade of dopamine D1- or D2-receptor in the prefrontal cortex induces attentional impairment in the object-based attention test through different neuronal circuits in mice. Molecular Brain. 2021;14:43.","journal-title":"Molecular Brain"},{"key":"3116_CR8","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1523\/JNEUROSCI.22-13-05619.2002","volume":"22","author":"SB Glickstein","year":"2002","unstructured":"Glickstein SB, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J Neurosci. 2002;22:5619\u201329.","journal-title":"J Neurosci"},{"key":"3116_CR9","doi-asserted-by":"crossref","unstructured":"Linden J, James AS, McDaniel C, Jentsch JD. Dopamine D2 receptors in dopaminergic neurons modulate performance in a reversal learning task in mice. eneuro. 2018;5:ENEURO.0229-17.2018.","DOI":"10.1523\/ENEURO.0229-17.2018"},{"key":"3116_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1523\/JNEUROSCI.2097-04.2005","volume":"25","author":"S Aalto","year":"2005","unstructured":"Aalto S, Br\u00fcck A, Laine M, N\u00e5gren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci. 2005;25:2471\u20137.","journal-title":"J Neurosci"},{"key":"3116_CR11","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1523\/JNEUROSCI.4284-11.2012","volume":"32","author":"DG Ghahremani","year":"2012","unstructured":"Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, De Shetler N, et al. Striatal dopamine D2\/D3 receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci. 2012;32:7316\u201324.","journal-title":"J Neurosci"},{"key":"3116_CR12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.neubiorev.2009.05.005","volume":"33","author":"A Egerton","year":"2009","unstructured":"Egerton A, Mehta MA, Montgomery AJ, Lappin JM, Howes OD, Reeves SJ, et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci Biobehav Rev. 2009;33:1109\u201332.","journal-title":"Neurosci Biobehav Rev"},{"key":"3116_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/brain\/awg119","volume":"126","author":"N Pavese","year":"2003","unstructured":"Pavese N, Andrews TC, Brooks DJ, Ho AK, Rosser AE, Barker RA, et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington\u2019s disease: a PET study. Brain. 2003;126:1127\u201335.","journal-title":"Brain"},{"key":"3116_CR14","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.bpsgos.2022.10.003","volume":"3","author":"JC Williams","year":"2023","unstructured":"Williams JC, Zheng ZJ, Tubiolo PN, Luceno JR, Gil RB, Girgis RR, et al. Medial prefrontal cortex dysfunction mediates working memory deficits in patients with schizophrenia. Biol Psychiatry Glob Open Sci. 2023;3:990\u20131002.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"3116_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/schbul\/sby076","volume":"45","author":"N Rao","year":"2019","unstructured":"Rao N, Northoff G, Tagore A, Rusjan P, Kenk M, Wilson A, et al. Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task: a [11C]FLB 457 positron emission tomography study. Schizophr Bull. 2019;45:670\u20139.","journal-title":"Schizophr Bull"},{"key":"3116_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0149-7634(02)00065-9","volume":"26","author":"V Kaasinen","year":"2002","unstructured":"Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson\u2019s disease. Neurosci Biobehav Rev. 2002;26:785\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"3116_CR17","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/brain\/awn054","volume":"131","author":"N Sawamoto","year":"2008","unstructured":"Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson\u2019s disease. Brain. 2008;131:1294\u2013302.","journal-title":"Brain"},{"key":"3116_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","volume":"132","author":"MC Lobo","year":"2022","unstructured":"Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev. 2022;132:324\u201361.","journal-title":"Neurosci Biobehav Rev"},{"key":"3116_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2024","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403:160\u201370.","journal-title":"Lancet"},{"key":"3116_CR20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/archpsyc.63.11.1189","volume":"63","author":"JL Reilly","year":"2006","unstructured":"Reilly JL, Harris MSH, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006;63:1189\u201397.","journal-title":"Arch Gen Psychiatry"},{"key":"3116_CR21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/schbul\/sbr189","volume":"39","author":"H Sakurai","year":"2012","unstructured":"Sakurai H, Bies RR, Stroup ST, Keefe RSE, Rajji TK, Suzuki T, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. 2012;39:564\u201374.","journal-title":"Schizophrenia Bulletin"},{"key":"3116_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bmj.314.7076.266","volume":"314","author":"R McShane","year":"1997","unstructured":"McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. Bmj. 1997;314:266\u201370.","journal-title":"Bmj"},{"key":"3116_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00127-019-01819-2","volume":"55","author":"J Thompson","year":"2020","unstructured":"Thompson J, Stansfeld JL, Cooper RE, Morant N, Crellin NE, Moncrieff J. Experiences of taking neuroleptic medication and impacts on symptoms, sense of self and agency: a systematic review and thematic synthesis of qualitative data. Soc Psychiatry Psychiatr Epidemiol. 2020;55:151\u201364.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"3116_CR24","doi-asserted-by":"crossref","unstructured":"Feber L, Peter NL, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al. Antipsychotic drugs and cognitive function: a systematic review and network meta-analysis. JAMA Psychiatry. 2025;82:47\u201356.","DOI":"10.1001\/jamapsychiatry.2024.2890"},{"key":"3116_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00406-016-0723-4","volume":"267","author":"A Wolf","year":"2017","unstructured":"Wolf A, Leucht S, Pajonk F-G. Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci. 2017;267:187\u201398.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"3116_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1192\/bjp.2023.57","volume":"223","author":"O Howes","year":"2023","unstructured":"Howes O, Fusar-Poli P, Osugo M. Treating negative symptoms of schizophrenia: current approaches and future perspectives. Br J Psychiatry. 2023;223:332\u20135.","journal-title":"Br J Psychiatry"},{"key":"3116_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02895-4","volume":"20","author":"JA Dennis","year":"2020","unstructured":"Dennis JA, Gittner LS, Payne JD, Nugent K. Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013-2018. BMC Psychiatry. 2020;20:483.","journal-title":"BMC Psychiatry"},{"key":"3116_CR28","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","volume":"27","author":"\u00d3 H\u00e1lfd\u00e1narson","year":"2017","unstructured":"H\u00e1lfd\u00e1narson \u00d3, Zo\u00ebga H, Aagaard L, Bernardo M, Brandt L, Fust\u00e9 AC, et al. International trends in antipsychotic use: a study in 16 countries, 2005\u20132014. European Neuropsychopharmacology. 2017;27:1064\u201376.","journal-title":"European Neuropsychopharmacology"},{"key":"3116_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1037\/0735-7044.120.3.497","volume":"120","author":"MJ Frank","year":"2006","unstructured":"Frank MJ, O\u2019Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci. 2006;120:497\u2013517.","journal-title":"Behav Neurosci"},{"key":"3116_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00213-016-4454-z","volume":"234","author":"HNA Logemann","year":"2017","unstructured":"Logemann HNA, B\u00f6cker KBE, Deschamps PKH, van Harten PN, Koning J, Kemner C, et al. Haloperidol 2 mg impairs inhibition but not visuospatial attention. Psychopharmacology. 2017;234:235\u201344.","journal-title":"Psychopharmacology"},{"key":"3116_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/JCP.0b013e318272d10c","volume":"32","author":"Y-C Chung","year":"2012","unstructured":"Chung Y-C, Park T-W, Yang J-C, Huang G-B, Zhao T, Oh K-Y, et al. Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol. J Clin Psychopharmacol. 2012;32:778\u201386.","journal-title":"J Clin Psychopharmacol"},{"key":"3116_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.schres.2006.03.033","volume":"85","author":"H Saeedi","year":"2006","unstructured":"Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res. 2006;85:222\u201331.","journal-title":"Schizophr Res"},{"key":"3116_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s002130050396","volume":"133","author":"G Lynch","year":"1997","unstructured":"Lynch G, King DJ, Green JF, Byth W, Wilson-Davis K. The effects of haloperidol on visual search, eye movements and psychomotor performance. Psychopharmacology (Berl). 1997;133:233\u20139.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004714-199906000-00003","volume":"19","author":"JG Ramaekers","year":"1999","unstructured":"Ramaekers JG, Louwerens JW, Muntjewerff ND, Milius H, de Bie A, Rosenzweig P, et al. Psychomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (Amisulpride) and a classic (Haloperidol) antipsychotic. J Clin Psychopharmacol. 1999;19:209\u201321.","journal-title":"J Clin Psychopharmacol"},{"key":"3116_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1162\/jocn.1997.9.3.330","volume":"9","author":"M Luciana","year":"1997","unstructured":"Luciana M, Collins PF. Dopaminergic modulation of working memory for spatial but not object cues in normal humans. J Cogn Neurosci. 1997;9:330\u201347.","journal-title":"J Cogn Neurosci"},{"key":"3116_CR36","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00213-004-1899-2","volume":"176","author":"MA Mehta","year":"2004","unstructured":"Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology (Berl). 2004;176:331\u201342.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00213-009-1634-0","volume":"207","author":"CM Dodds","year":"2009","unstructured":"Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E, et al. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl). 2009;207:35\u201345.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.56","volume":"7","author":"M Naef","year":"2017","unstructured":"Naef M, M\u00fcller U, Linssen A, Clark L, Robbins TW, Eisenegger C. Effects of dopamine D2\/D3 receptor antagonism on human planning and spatial working memory. Transl Psychiatry. 2017;7:e1107.","journal-title":"Transl Psychiatry"},{"key":"3116_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/0269881104042614","volume":"18","author":"SL Barrett","year":"2004","unstructured":"Barrett SL, Bell R, Watson D, King DJ. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol. 2004;18:156\u201372.","journal-title":"J Psychopharmacol"},{"key":"3116_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/026988110101500211","volume":"15","author":"D McCartan","year":"2001","unstructured":"McCartan D, Bell R, Green JF, Campbell C, Trimble K, Pickering A, et al. The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers. J Psychopharmacol. 2001;15:96\u2013104.","journal-title":"J Psychopharmacol"},{"key":"3116_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s002130051102","volume":"146","author":"MA Mehta","year":"1999","unstructured":"Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson\u2019s disease. Psychopharmacology (Berl). 1999;146:162\u201374.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2020.172999","volume":"197","author":"I Poddar","year":"2020","unstructured":"Poddar I, Callahan PM, Hernandez CM, Pillai A, Yang X, Bartlett MG, et al. Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats. Pharmacol Biochem Behav. 2020;197:172999.","journal-title":"Pharmacol Biochem Behav"},{"key":"3116_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/026988119901300207","volume":"13","author":"JN Beuzen","year":"1999","unstructured":"Beuzen JN, Taylor N, Wesnes K, Wood A. A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. J Psychopharmacol. 1999;13:152\u20138.","journal-title":"J Psychopharmacol"},{"key":"3116_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1024\/1421-0185\/a000112","volume":"72","author":"L Corbin","year":"2013","unstructured":"Corbin L, Marquer J. Is Sternberg\u2019s memory scanning task really a short-term memory task? Swiss J Psychol. 2013;72:181\u201396.","journal-title":"Swiss J Psychol"},{"key":"3116_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0269881112466183","volume":"27","author":"T Veselinovi\u0107","year":"2013","unstructured":"Veselinovi\u0107 T, Schorn H, Vernaleken IB, Hiemke C, Zernig G, Gur R, et al. Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol. 2013;27:374\u201385.","journal-title":"J Psychopharmacol"},{"key":"3116_CR46","doi-asserted-by":"publisher","first-page":"400","DOI":"10.9758\/cpn.2019.17.3.400","volume":"17","author":"HJ Choi","year":"2019","unstructured":"Choi HJ, Im SJ, Park HR, Park S, Kim CE, Ryu S. Long-term effects of aripiprazole treatment during adolescence on cognitive function and dopamine D2 receptor expression in neurodevelopmentally normal rats. Clin Psychopharmacol Neurosci. 2019;17:400\u20138.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"3116_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1162\/jocn.1992.4.1.58","volume":"4","author":"M Luciana","year":"1992","unstructured":"Luciana M, Depue RA, Arbisi P, Leon A. Facilitation of working memory in humans by a D2 dopamine receptor agonist. J Cogn Neurosci. 1992;4:58\u201368.","journal-title":"J Cogn Neurosci"},{"key":"3116_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s002130100851","volume":"159","author":"MA Mehta","year":"2001","unstructured":"Mehta MA, Swainson R, Ogilvie AD, Sahakian J, Robbins TW. Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Psychopharmacology (Berl). 2001;159:10\u201320.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR49","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1523\/JNEUROSCI.0601-07.2007","volume":"27","author":"R Cools","year":"2007","unstructured":"Cools R, Sheridan M, Jacobs E, D\u2019Esposito M. Impulsive personality predicts dopamine-dependent changes in frontostriatal activity during component processes of working memory. J Neurosci. 2007;27:5506\u201314.","journal-title":"J Neurosci"},{"key":"3116_CR50","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40263-020-00718-4","volume":"34","author":"N Keks","year":"2020","unstructured":"Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative tolerability of dopamine D2\/3 receptor partial agonists for schizophrenia. CNS Drugs. 2020;34:473\u2013507.","journal-title":"CNS Drugs"},{"key":"3116_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104568","volume":"135","author":"M Osugo","year":"2022","unstructured":"Osugo M, Whitehurst T, Shatalina E, Townsend L, O\u2019Brien O, Mak TLA, et al. Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Neurosci Biobehav Rev. 2022;135:104568.","journal-title":"Neurosci Biobehav Rev"},{"key":"3116_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"DM Taylor","year":"2021","unstructured":"Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. Wiley; 2021."},{"key":"3116_CR53","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3758\/s13428-019-01237-x","volume":"52","author":"AL Anwyl-Irvine","year":"2020","unstructured":"Anwyl-Irvine AL, Massonni\u00e9 J, Flitton A, Kirkham N, Evershed JK. Gorilla in our midst: An online behavioral experiment builder. Behav Res Methods. 2020;52:388\u2013407.","journal-title":"Behav Res Methods"},{"key":"3116_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.2044-8341.1974.tb02285.x","volume":"47","author":"A Bond","year":"1974","unstructured":"Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol. 1974;47:211\u20138.","journal-title":"Br J Med Psychol"},{"key":"3116_CR55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0028-3932(97)00015-8","volume":"35","author":"IH Robertson","year":"1997","unstructured":"Robertson IH, Manly T, Andrade J, Baddeley BT, Yiend J. \u2018Oops!\u2019: Performance correlates of everyday attentional failures in traumatic brain injured and normal subjects. Neuropsychologia. 1997;35:747\u201358.","journal-title":"Neuropsychologia"},{"key":"3116_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2016.10.011","volume":"181","author":"M Starc","year":"2017","unstructured":"Starc M, Murray JD, Santamauro N, Savic A, Diehl C, Cho YT, et al. Schizophrenia is associated with a pattern of spatial working memory deficits consistent with cortical disinhibition. Schizophr Res. 2017;181:107\u201316.","journal-title":"Schizophr Res"},{"key":"3116_CR57","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1126\/science.1825731","volume":"251","author":"T Sawaguchi","year":"1991","unstructured":"Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251:947\u201350.","journal-title":"Science"},{"key":"3116_CR58","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1177\/00187208211060708","volume":"65","author":"JA Dang","year":"2022","unstructured":"Dang JA, Shaw TH, McKnight PE, Helton WS. A closer look at warning cues on the sustained attention to response task performance. Hum Factors. 2022;65:1793\u2013803.","journal-title":"Hum Factors"},{"key":"3116_CR59","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3758\/s13428-018-1076-x","volume":"51","author":"HR Liesefeld","year":"2019","unstructured":"Liesefeld HR, Janczyk M. Combining speed and accuracy to control for speed-accuracy trade-offs(?). Behav Res Methods. 2019;51:40\u201360.","journal-title":"Behav Res Methods"},{"key":"3116_CR60","doi-asserted-by":"publisher","unstructured":"Lohse K, Kozlowski A, Strube MJ. Model Specification in Mixed-Effects Models: A Focus on Random Effects. Communications in Kinesiology. 2023;1. https:\/\/doi.org\/10.51224\/cik.2023.52.","DOI":"10.51224\/cik.2023.52"},{"key":"3116_CR61","doi-asserted-by":"crossref","unstructured":"Bond IG, Machida K, Johnson KA. Daily arousal variation has little effect on sustained attention performance. Curr Psychol. 2024;43:2690\u2013703.","DOI":"10.1007\/s12144-023-04473-9"},{"key":"3116_CR62","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B (Methodol)"},{"key":"3116_CR63","unstructured":"Wuensch K. Comparing correlation coefficients, slopes, and intercepts. Statistics Lessons. 2007."},{"key":"3116_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.2044-8341.1976.tb02388.x","volume":"49","author":"M Herbert","year":"1976","unstructured":"Herbert M, Johns MW, Dor\u00e9 C. Factor analysis of analogue scales measuring subjective feelings before and after sleep. Br J Med Psychol. 1976;49:373\u20139.","journal-title":"Br J Med Psychol"},{"key":"3116_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56663-7","volume":"16","author":"M Osugo","year":"2025","unstructured":"Osugo M, Wall MB, Selvaggi P, Zahid U, Finelli V, Chapman GE, et al. Striatal dopamine D2\/D3 receptor regulation of human reward processing and behaviour. Nat Commun. 2025;16:1852.","journal-title":"Nat Commun"},{"key":"3116_CR66","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41386-025-02120-4","volume":"50","author":"P Selvaggi","year":"2025","unstructured":"Selvaggi P, Osugo M, Zahid U, Dipasquale O, Whitehurst T, Onwordi E, et al. Antipsychotics cause reversible structural brain changes within one week. Neuropsychopharmacology. 2025;50:1275\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"3116_CR67","doi-asserted-by":"crossref","unstructured":"Zahid U, Osugo M, Selvaggi P, Lythgoe D, Fortunato C, Diederen K, Kiemes A, Wall M, Whitehurst T, Onwordi EC, Statton B, Berry A, Dimitrov M, Lau KYR, McCutcheon R, Murray R, Reis Marques T, Mehta M, Howes O. The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: a double-blind, randomised, placebo-controlled 1H-MRS cross-over study in healthy volunteers. Br J Psychiatry. 2025. Accepted\/In press","DOI":"10.1192\/bjp.2025.10319"},{"key":"3116_CR68","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/JCP.0000000000001921","volume":"44","author":"GE Chapman","year":"2024","unstructured":"Chapman GE, Osugo M, de Marvao A, Howes OD. Aripiprazole-associated QT prolongation in a healthy study volunteer: a case report and literature review. J Clin Psychopharmacol. 2024;44:591\u20134.","journal-title":"J Clin Psychopharmacol"},{"key":"3116_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","volume":"25","author":"XM Hart","year":"2024","unstructured":"Hart XM, Gr\u00fcnder G, Ansermot N, Conca A, Corruble E, Crettol S, et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics. World J Biol Psychiatry. 2024;25:451\u2013536.","journal-title":"World J Biol Psychiatry"},{"key":"3116_CR70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1037\/a0036295","volume":"123","author":"L Wright","year":"2014","unstructured":"Wright L, Lipszyc J, Dupuis A, Thayapararajah SW, Schachar R. Response inhibition and psychopathology: a meta-analysis of go\/no-go task performance. J Abnorm Psychol. 2014;123:429\u201339.","journal-title":"J Abnorm Psychol"},{"key":"3116_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41130-y","volume":"14","author":"K Chakroun","year":"2023","unstructured":"Chakroun K, Wiehler A, Wagner B, Mathar D, Ganzer F, van Eimeren T, et al. Dopamine regulates decision thresholds in human reinforcement learning in males. Nat Commun. 2023;14:5369.","journal-title":"Nat Commun"},{"key":"3116_CR72","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/14.2.2","volume":"14","author":"B Pearson","year":"2014","unstructured":"Pearson B, Ra\u0161kevi\u010dius J, Bays PM, Pertzov Y, Husain M. Working memory retrieval as a decision process. J Vis. 2014;14:2.","journal-title":"J Vis"},{"key":"3116_CR73","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41593-018-0152-y","volume":"21","author":"JD Berke","year":"2018","unstructured":"Berke JD. What does dopamine mean? Nat Neurosci. 2018;21:787\u201393.","journal-title":"Nat Neurosci"},{"key":"3116_CR74","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.tins.2018.04.006","volume":"41","author":"A Perugini","year":"2018","unstructured":"Perugini A, Ditterich J, Shaikh AG, Knowlton BJ, Basso MA. Paradoxical decision-making: a framework for understanding cognition in Parkinson\u2019s disease. Trends Neurosci. 2018;41:512\u201325.","journal-title":"Trends Neurosci"},{"key":"3116_CR75","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.baga.2013.11.001","volume":"4","author":"DK Leventhal","year":"2014","unstructured":"Leventhal DK, Stoetzner C, Abraham R, Pettibone J, DeMarco K, Berke JD. Dissociable effects of dopamine on learning and performance within sensorimotor striatum. Basal Ganglia. 2014;4:43\u201354.","journal-title":"Basal Ganglia"},{"key":"3116_CR76","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.bbr.2018.08.030","volume":"356","author":"BJ De Corte","year":"2019","unstructured":"De Corte BJ, Wagner LM, Matell MS, Narayanan NS. Striatal dopamine and the temporal control of behavior. Behav Brain Res. 2019;356:375\u20139.","journal-title":"Behav Brain Res"},{"key":"3116_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07577-y","volume":"7","author":"L B\u00e4ckman","year":"2017","unstructured":"B\u00e4ckman L, Waris O, Johansson J, Andersson M, Rinne JO, Alakurtti K, et al. Increased dopamine release after working-memory updating training: Neurochemical correlates of transfer. Sci Rep. 2017;7:7160.","journal-title":"Sci Rep"},{"key":"3116_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05214-4","volume":"9","author":"S Duvarci","year":"2018","unstructured":"Duvarci S, Simpson EH, Schneider G, Kandel ER, Roeper J, Sigurdsson T. Impaired recruitment of dopamine neurons during working memory in mice with striatal D2 receptor overexpression. Nat Commun. 2018;9:2822.","journal-title":"Nat Commun"},{"key":"3116_CR79","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00213-006-0654-2","volume":"191","author":"T Hamamura","year":"2007","unstructured":"Hamamura T, Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology. 2007;191:741\u20133.","journal-title":"Psychopharmacology"},{"key":"3116_CR80","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/0269881108089586","volume":"23","author":"L Dahan","year":"2009","unstructured":"Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol. 2009;23:177\u201389.","journal-title":"J Psychopharmacol"},{"key":"3116_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.bandc.2013.02.002","volume":"82","author":"L Carter","year":"2013","unstructured":"Carter L, Russell PN, Helton WS. Target predictability, sustained attention, and response inhibition. Brain Cogn. 2013;82:35\u201342.","journal-title":"Brain Cogn"},{"key":"3116_CR82","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bandc.2011.08.007","volume":"77","author":"H Stevenson","year":"2011","unstructured":"Stevenson H, Russell PN, Helton WS. Search asymmetry, sustained attention, and response inhibition. Brain Cogn. 2011;77:215\u201322.","journal-title":"Brain Cogn"},{"key":"3116_CR83","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00213-008-1127-6","volume":"199","author":"DM Eagle","year":"2008","unstructured":"Eagle DM, Bari A, Robbins TW. The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go\/no-go tasks. Psychopharmacology (Berl). 2008;199:439\u201356.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR84","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1177\/0269881113480988","volume":"27","author":"SR Chamberlain","year":"2013","unstructured":"Chamberlain SR, Robbins TW. Noradrenergic modulation of cognition: therapeutic implications. J Psychopharmacol. 2013;27:694\u2013718.","journal-title":"J Psychopharmacol"},{"key":"3116_CR85","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.bbr.2010.12.039","volume":"219","author":"ZU Khan","year":"2011","unstructured":"Khan ZU, Muly EC. Molecular mechanisms of working memory. Behav Brain Res. 2011;219:329\u201341.","journal-title":"Behav Brain Res"},{"key":"3116_CR86","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00213-006-0404-5","volume":"188","author":"SB Floresco","year":"2006","unstructured":"Floresco SB, Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology (Berl). 2006;188:567\u201385.","journal-title":"Psychopharmacology (Berl)"},{"key":"3116_CR87","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","volume":"69","author":"R Cools","year":"2011","unstructured":"Cools R, D\u2019Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 2011;69:e113\u201325.","journal-title":"Biol Psychiatry"},{"key":"3116_CR88","doi-asserted-by":"publisher","first-page":"e83161","DOI":"10.7554\/eLife.83161","volume":"12","author":"R van den Bosch","year":"2023","unstructured":"van den Bosch R, Hezemans FH, M\u00e4\u00e4tt\u00e4 JI, Hofmans L, Papadopetraki D, Verkes RJ, et al. Evidence for absence of links between striatal dopamine synthesis capacity and working memory capacity, spontaneous eye-blink rate, and trait impulsivity. Elife. 2023;12:e83161.","journal-title":"Elife"},{"key":"3116_CR89","doi-asserted-by":"publisher","first-page":"967941","DOI":"10.3389\/fpsyt.2022.967941","volume":"13","author":"U Zahid","year":"2022","unstructured":"Zahid U, McCutcheon RA, Borgan F, Jauhar S, Pepper F, Nour MM, et al. The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: a (1)H-MRS study in first-episode psychosis patients. Front Psychiatry. 2022;13:967941.","journal-title":"Front Psychiatry"},{"key":"3116_CR90","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1001\/jamapsychiatry.2019.3993","volume":"77","author":"AJ Fett","year":"2020","unstructured":"Fett AJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, et al. Long-term changes in cognitive functioning in individuals with psychotic disorders: findings from the suffolk county mental health project. JAMA Psychiatry. 2020;77:387\u201396.","journal-title":"JAMA Psychiatry"},{"key":"3116_CR91","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. 2020;172:107704.","journal-title":"Neuropharmacology"},{"key":"3116_CR92","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.biopsych.2023.04.004","volume":"94","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Harrison PJ, Howes OD, McGuire PK, Taylor DM, Pillinger T. Data-driven taxonomy for antipsychotic medication: a new classification system. Biol Psychiatry. 2023;94:561\u20138.","journal-title":"Biol Psychiatry"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03116-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:04:49Z","timestamp":1760598289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03116-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03116-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ODH has received investigator-initiated research funding from and\/or participated in advisory\/speaker meetings organised by Angelini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack\/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris\/ Mylan. He was previously a part-time employee of Lundbeck A\/v. Neither ODH nor his family have holdings\/a financial stake in any pharmaceutical company. ODH has a patent for the use of dopaminergic imaging. MW is an employee of Perceptive Inc., London. TRM is an employee and have shares of Pasithea Therapeutics. Other authors have reported no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}